Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 18/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042345 | 0.86 | GRM5 (0.61) | GRM5KCNH2FFAR1 | |
| SCHEMBL2009532 | 0.86 | GRM5 (0.49) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL5045983 | 0.82 | GRM5 (0.49) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL5038553 | 0.82 | GRM5 (0.44) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL981728 | 0.79 | GRM5 (0.62) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL5042934 | 0.79 | GRM5 (0.48) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2174066 | 0.78 | GRM5 (0.57) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2175568 | 0.77 | GRM5 (0.63) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2174588 | 0.77 | GRM5 (0.63) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL5043887 | 0.76 | GRM5 (0.46) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644351-B1 | Imidazole derivatives and their use in the treatment of mGluR5 receptor mediated disorders | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-7091222-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1644351-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003117-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009878-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009878-A1 | Imidazole derivatives | GRIK5, GRM5, GRIK4 | GRM5 2/4885KCNH2 78/4885ADRB3 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.